Ubs Oncology Impact Fund L.P. Cullinan Oncology, Inc. (CGEM) insider trading activity

Ubs Oncology Impact Fund L.P. is > 10% Shareholder of Cullinan Oncology, Inc.. Currently has a direct ownership of 7.65 Million shares of CGEM, which is worth approximately $93.8 Million. The most recent transaction as insider was on Sep 16, 2021, when has been sold 3,124 shares (Common Stock) at a price of $29.06 per share, resulting in proceeds of $90,783. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 7.65M

0% 3M change

0% 12M change

Total Value Held $93.8 Million

UBS Oncology Impact Fund L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 16 2021	SELL Open market or private sale	$90,783 $29.06 p/Share	3,124 Reduced 0.04%	7,648,268 Common Stock
Sep 15 2021	SELL Open market or private sale	$187,353 $29.16 p/Share	6,425 Reduced 0.08%	7,651,392 Common Stock
Sep 14 2021	SELL Open market or private sale	$207,282 $29.17 p/Share	7,106 Reduced 0.09%	7,657,817 Common Stock
Sep 13 2021	SELL Open market or private sale	$104,615 $29.1 p/Share	3,595 Reduced 0.05%	7,664,923 Common Stock
Sep 10 2021	SELL Open market or private sale	$172,236 $29.04 p/Share	5,931 Reduced 0.08%	7,668,518 Common Stock
Sep 09 2021	SELL Open market or private sale	$402,887 $29.35 p/Share	13,727 Reduced 0.18%	7,674,449 Common Stock
Sep 08 2021	SELL Open market or private sale	$315,611 $29.11 p/Share	10,842 Reduced 0.14%	7,688,176 Common Stock
Sep 07 2021	SELL Open market or private sale	$727,946 $29.04 p/Share	25,067 Reduced 0.32%	7,699,018 Common Stock
Sep 03 2021	SELL Open market or private sale	$376,838 $29.6 p/Share	12,731 Reduced 0.16%	7,724,085 Common Stock
Sep 02 2021	SELL Open market or private sale	$464,201 $29.46 p/Share	15,757 Reduced 0.2%	7,736,816 Common Stock
Sep 01 2021	SELL Open market or private sale	$168,392 $29.47 p/Share	5,714 Reduced 0.07%	7,752,573 Common Stock
Aug 31 2021	SELL Open market or private sale	$84,544 $29.79 p/Share	2,838 Reduced 0.04%	7,758,287 Common Stock
Aug 30 2021	SELL Open market or private sale	$908,329 $29.3 p/Share	31,001 Reduced 0.4%	7,761,125 Common Stock
Aug 27 2021	SELL Open market or private sale	$388,555 $29.09 p/Share	13,357 Reduced 0.17%	7,792,126 Common Stock
Aug 25 2021	SELL Open market or private sale	$49,831 $29.09 p/Share	1,713 Reduced 0.02%	7,805,483 Common Stock
Aug 24 2021	SELL Open market or private sale	$1,498,233 $29.48 p/Share	50,822 Reduced 0.65%	7,807,196 Common Stock
Aug 23 2021	SELL Open market or private sale	$1,553,281 $29.11 p/Share	53,359 Reduced 0.67%	7,858,018 Common Stock
Aug 11 2021	SELL Open market or private sale	$72,915 $29.05 p/Share	2,510 Reduced 0.03%	7,911,377 Common Stock
Jan 12 2021	BUY Open market or private purchase	$6,300,000 $21.0 p/Share	300,000 Added 3.65%	7,913,887 Common Stock
Jan 12 2021	BUY Conversion of derivative security	-	7,613,887 Added 50.0%	7,613,887 Common Stock

Also insider at

TCRR

TCR2 THERAPEUTICS INC. Healthcare

> 10% Shareholder

HARP

Harpoon Therapeutics, Inc. Healthcare

> 10% Shareholder

ONCR

Oncorus, Inc. Healthcare

> 10% Shareholder

UOI